AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions thereof.

Claims 1-42 (cancelled).

Claim 43 (currently amended): A method for the acute or prophylactic treatment ~~or prevention~~ of a disease in a mammal where a phosphodiesterase isoenzyme inhibitor and/or a bronchodilator would be expected to be of benefit, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I:



I

wherein

each of R^1 and R^2 independently represents a C_{1-6} alkyl or C_{2-7} acyl group;
R^5 represents a hydrogen atom or a C_{1-3} alkyl, C_{2-3} alkenyl or C_{2-3} alkynyl group;
R^6 represents a hydrogen atom or a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, amino, C_{1-6} alkylamino, di(C_{1-6}) alkylamino or C_{2-7} acylamino group;

each of R^7 and R^8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy,
C_{3-6} cycloalkyl; and
R^9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy or C_{3-6} cycloalkyl group;
X represents ~~OCH_2 or~~ a group CR^3R^4, wherein each of R^3 and R^4 independently represents a hydrogen atom or a C_{1-3} alkyl group;
each of R^{10} and R^{11} independently represents a hydrogen atom, a C_{1-3} alkyl, C_{3-6} cycloalkyl or phenyl group;
Y represents an oxygen atom or a group $CHNO_2$, NCN, NH or NNO_2;
n is an integer from 2 to 4;
or a salt thereof.

Claim 44 (currently amended): A method for the <u>acute or prophylactic</u> treatment ~~or prevention of~~ asthma in a mammal, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I:



I

wherein

each of R^1 and R^2 independently represents a C_{1-6} alkyl or C_{2-7} acyl group;

R^5 represents a hydrogen atom or a C_{1-3} alkyl, C_{2-3} alkenyl or C_{2-3} alkynyl group;
R^6 represents a hydrogen atom or a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, amino, C_{1-6} alkylamino, di(C_{1-6}) alkylamino or C_{2-7} acylamino group;
each of R^7 and R^8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy,
C_{3-6} cycloalkyl; and
R^9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy or C_{3-6} cycloalkyl group;
X represents ~~OCH_2 or~~ a group CR^3R^4, wherein each of R^3 and R^4 independently represents a hydrogen atom or a C_{1-3} alkyl group;
each of R^{10} and R^{11} independently represents a hydrogen atom, a C_{1-3} alkyl, C_{3-6} cycloalkyl or phenyl group;
Y represents an oxygen atom or a group $CHNO_2$, NCN, NH or NNO_2;
n is an integer from 2 to 4;
or a salt thereof.

Claim 45 (currently amended): A method for the acute or prophylactic treatment ~~or prevention~~ of chronic obstructive pulmonary disease (COPD) in a mammal, which method comprises administering to said mammal an effective, non-toxic amount of a compound of general formula I:



I

wherein

each of R^1 and R^2 independently represents a C_{1-6} alkyl or C_{2-7} acyl group;
R^5 represents a hydrogen atom or a C_{1-3} alkyl, C_{2-3} alkenyl or C_{2-3} alkynyl group;
R^6 represents a hydrogen atom or a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, amino, C_{1-6} alkylamino, di(C_{1-6}) alkylamino or C_{2-7} acylamino group;
each of R^7 and R^8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy,
C_{3-6} cycloalkyl; and
R^9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-7} acyl, C_{1-6} alkylthio, C_{1-6} alkoxy or C_{3-6} cycloalkyl group;
X represents ~~OCH_2 or~~ a group CR^3R^4, wherein each of R^3 and R^4 independently represents a hydrogen atom or a C_{1-3} alkyl group;
each of R^{10} and R^{11} independently represents a hydrogen atom, a C_{1-3} alkyl, C_{3-6} cycloalkyl or phenyl group;
Y represents an oxygen atom or a group $CHNO_2$, NCN, NH or NNO_2;
n is an integer from 2 to 4;
or a salt thereof.

Claim 46 (currently amended): A method as claimed in any of claims 43, 44 or 45, wherein independently or in any compatible combination:

each of R^1 and R^2 independently represent[[s]] a C_{1-6} alkyl;
~~R^1 and R^2 are the same as each other;~~
each of R^3 and R^4 represents a hydrogen atom;
R^5 represents a hydrogen atom;
R^6 represents a hydrogen atom;
each of R^7 and R^8 independently represent[[s]] a C_{1-6} alkyl;
~~R^7 and R^8 are the same as each other;~~
R^9 represents a halogen atom or a methyl or acetyl group;
Y represents an oxygen atom or a group $CHNO_2$; and
n is 2.

Claim 47 (previously presented): A method as claimed in any of claims 43 to 45, wherein the compound is administered by aerosol.

Claim 48 (previously presented): A method as claimed in any of claims 43 to 45, wherein the animal is a human.

Claims 49-50 (cancelled).

Claim 51 (currently amended): A method as claimed in any of claims 43 to 45, wherein each of R^1 and R^2 represents a C_{1-4} alkyl[[,]] group; and each of R^7 and R^8 represents a _methyl, ethyl or isopropyl group.

Claim 52 (previously presented): A method as claimed in any of claims 43 to 45, wherein the compound of general formula I is selected from the group consisting of:

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(*N*-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N'*-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-[1-(*N'*-methyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3- [N-[1-(*N'*-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-[1-(*N'*, *N'*-dimethyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N'*-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one;

9, 10-Dimethoxy-3-[2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-3-[*N*-(*N'*-nitro)-2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-[*N*-(*N'*-Cyclohexylcarbamoyl)-2-aminoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-2-aminoethyl)-9,10-dimethoxy-2-(2-methylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-2-aminoethyl)-2-(2,6-diisopropylphenylimino)-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-4-aminobutyl)-9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one; and

3-[*N*-(*N'*-Cyano-*N''*-methyl)-2-guanidinoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)- 3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.